Galderma Group AG
GALD
Company Profile
Business description
Galderma was formed in 1981 as a joint venture between Nestle and L’Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma’s science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
Contact
Zahlerweg 10
Zug6300
CHET: +41 584558592
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
7,600
Stocks News & Analysis
stocks
Chart of the Week: Recent selloffs in this ASX sector opens doors to opportunity
Ongoing rate hikes have investors spooked.
stocks
ASX dividend champions: Stocks, ETFs and LICs
Mark and Shani run through lessons for ASX stocks, ETFs and LICs that have delivered over the past decade.
stocks
SpaceX’s IPO filing: Big spending, big losses
The first public financials from Elon Musk’s company highlight Starlink’s revenue power and increased spending on AI.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,840.80 | 9.50 | -0.11% |
| CAC 40 | 8,099.22 | 18.20 | -0.22% |
| DAX 40 | 24,696.70 | 40.54 | -0.16% |
| Dow JONES (US) | 50,009.35 | 645.47 | 1.31% |
| FTSE 100 | 10,392.87 | 39.47 | -0.38% |
| HKSE | 25,386.52 | 264.60 | -1.03% |
| NASDAQ | 26,270.36 | 399.65 | 1.54% |
| Nikkei 225 | 61,684.14 | 1,879.73 | 3.14% |
| NZX 50 Index | 12,878.07 | 117.04 | 0.92% |
| S&P 500 | 7,432.97 | 79.36 | 1.08% |
| S&P/ASX 200 | 8,621.70 | 6.30 | -0.07% |
| SSE Composite Index | 4,077.28 | 84.91 | -2.04% |